In Memoriam: Dame Bridget Ogilvie

In memory of Dame Bridget Ogilvie, an esteemed scientist and research leader who transformed the Lister Institute.

The Lister Institute is deeply saddened by the death of Dame Bridget Ogilvie, a distinguished parasitologist, science leader and public advocate for research whose influence extended from the laboratory bench to the highest levels of biomedical funding and institutional leadership. For the Lister Institute, her loss is felt especially keenly because she was such a transformative trustee: the person who helped secure the Institute’s future by reshaping its awards at a moment of real financial pressure and uncertainty.

Across a career that spanned parasitology, tropical medicine, science policy, public engagement and philanthropy, Bridget combined intellectual authority with strategic courage. She became internationally recognised for her research on immune responses to parasitic worms, went on to lead the Wellcome as Director from 1991 to 1998, helped establish the Sanger Institute, and later brought that same clarity of judgement to the Lister Institute, where she chaired the Governing Body through turbulent times from 2002 to 2011.

From rural New South Wales to the frontiers of parasitology

Bridget Margaret Ogilvie was born in Glen Innes, New South Wales, in 1938, and her early life on a sheep property helped shape the scientific questions that would animate her career. As she later recalled, she saw at first hand the toll that parasitic disease could take on animal health, and this practical encounter with helminths and infection gave her an early sense that science mattered because it could solve urgent, real-world problems.

She studied first at the University of Queensland and then at the University of New England, where she graduated in 1960 with a Bachelor of Rural Science (Hons I) and the University Medal. A Commonwealth Scholarship then took her to Cambridge, where she completed a PhD on immunity to intestinal nematodes in 1964. Those years established the scientific foundations of a career that would begin in parasitology but would eventually influence the whole landscape of biomedical research.

After Cambridge, Bridget joined the National Institute for Medical Research in London, where she spent many years studying immune responses to parasitic infection and over two decades became internationally renowned in this field.

Even in these early years, colleagues and institutions recognised not only Bridget’s scientific excellence but her unusual breadth. In a 2005 honorary degree citation, Professor Margaret Sheil, then Vice-Chancellor (Research) of the University of Wollongong, Australia, described her as “a scientist of international standing whose passion for the promotion and the public understanding of science has inspired and empowered others.” That dual identity – rigorous scientist and advocate for science in society – defined her career in science leadership.

Tireless advocacy and leadership

In 1979 Bridget began her long association with the Wellcome Trust, initially through its tropical medicine portfolio and then, from 1991 to 1998, as Director. During those years she helped steer one of the most important research charities in the world through a period of expansion in global health, scientific ambition and public engagement. She is widely acknowledged for her role in enlarging Wellcome’s support for research in Africa and the Asia-Pacific.

One achievement in particular stands out. During Bridget’s directorship, Wellcome established the Sanger Institute, now part of the Wellcome Genome Campus, and helped shape its central role in world-leading international genome research. The significance of Bridget’s vision and leadership is today marked physically in the Bridget Ogilvie Building which opened at the campus in 2016, a firm recognition that her leadership helped create one of the UK’s defining modern biomedical science institutions.

Bridget’s influence extended far beyond Wellcome. She served on the boards of organisations across science, medicine, education and industry, including Cancer Research UK, Sense about Science, the Science Museum, AstraZeneca and the Medicines for Malaria Venture, of which she was the founding chairman. She was elected Fellow of the Academy of Medical Sciences in 1998, Fellow of the Royal Society in 2003, and later became a Companion of the Order of Australia and a Fellow of the Australian Academy of Science.

The woman who remade the Lister Institute

For the Lister Institute, however, Bridget’s most consequential legacy may lie in what she achieved after she took over as Chairman of the Governing Body in 2002 (she disliked the term 'chair' and preferred to be called chairman, according to Rory Guinness, a member of the Governing Body). At that point, the Institute faced a difficult and potentially defining moment. The old Fellowship scheme, though extraordinarily successful in nurturing outstanding researchers, had become increasingly hard to sustain. Research costs had risen sharply, and the dotcom bubble had burst, which affected Institute’s finances. Perhaps most significant, however, was that other major funders had entered the research fellowship funding space with more generous schemes; the value of Lister awards was uncompetitive and applications were in decline. Some researchers were turning down Lister Fellowships in favour of other funders.

Bridget realised that the Lister Fellowship scheme needed to change. She closed the Fellowships to new applicants and spearheaded efforts to reduce running costs. The Bushey Heath headquarters, known as “The White House”, was sold, and the Institute’s small staff moved to home working. These were difficult decisions, but they created the conditions for the Institute’s next bold step: the Lister Prize awards.

That reform was both practical and visionary. Instead of making long-term salary commitments, the Institute introduced a one-off award to a small number of outstanding early-career scientists each year – a model that could be sustained financially while remaining transformative for recipients. Crucially, Bridget preserved the principle that had always made Lister funding distinctive: trust in the researcher. As she herself said in the 125th anniversary magazine, “The Prize awards allowed as much freedom as possible for the recipient to decide on what and when to spend the funds.”

That sentence captures something essential about Bridget’s understanding of research. She recognised that young scientists at pivotal moments in their careers often need not only money, but freedom: room to pursue difficult, unconventional or high-risk ideas that more prescriptive schemes may overlook. And the new Lister Prize award made clear that in an environment where many grants were becoming increasingly restrictive, the Institute offered a unique scheme that gave freedom to its recipients over how to use the funding.

A lasting legacy

When Bridget stepped down in 2011, her successor Sir Alex Markham paid tribute in emphatic terms. “Thanks to her stewardship and vision over the last nine years, the Institute has launched its very successful Prize Fellowship scheme, and latterly introduced a popular Summer Studentship programme,” he wrote in the 2011 Annual Report. “This has been achieved from an initial difficult financial position and during periods of major stock market weakness and economic turmoil… The Lister should be very grateful that it had Dame Bridget at the helm to help formulate and guide these major changes.”

Those words confirm what many in the Lister community already know: Bridget redefined its funding identity for the 21st century. The modern Lister Prize – flexible, selective, prestigious and focused on talented early-career researchers – is one of the clearest expressions of her legacy, which is seen every year in the scientists the Lister supports. Today, the Lister Prize gives its winners confidence, freedom, prestige and a supportive scientific community at one of the hardest stages of a research career.

Whether as a parasitologist, director, chairman, trustee or advocate, Bridget believed in enabling people and ideas to flourish. She brought scientific seriousness to public life, and practical judgement to institutions that needed to adapt without losing sight of their purpose. For the Lister Institute, that purpose was to back outstanding biomedical researchers in ways that could change lives. Bridget ensured the Institute could continue to do exactly that.

Dame Bridget Ogilvie leaves behind an extraordinary record of service to science. But at the Lister, her legacy is not only remembered – it is renewed every time a Prize winner receives the freedom to pursue an idea that others might hesitate to back. That may be the most fitting memorial of all.

Tributes